involving nanotextured Endoskeleton devices to others who have had competing devices implanted.
This evidence, generated not by Titan itself but by other organizations involved with procedures where patients have devices implanted, such as hospitals, puts the company in a “unique position” where it can “look at its [own] results versus everyone else in the industry,” Ullrich says.
“[Insurers] generally trust real-world evidence as generated by other parties more than by companies that are generating it themselves,” he adds.
Even though sales outside the U.S. represented less than 2 percent of Titan’s total revenues in 2016, making or continuing a push into other countries could become a bigger focus at the company in coming years. In November, Titan announced that doctors in Australia successfully completed the first procedures involving Endoskeleton fusion devices in that country.
